The scientists behind the trial, which is looking into a range of potential treatments for COVID-19, evaluated aspirin's effects on nearly 15,000 hospitalised patients infected with the novel coronavirus.
In the study, named RECOVERY, a little less than half of the patients were selected at random and given 150mg of aspirin once a day, and the remaining were given usual care alone.